Table 2.
Odds ratio of various PPIs from the network meta-analysis for adverse events.
| OR | OME | PAN | LAN | RAB | ILA | RAN | FAM | PLA |
|---|---|---|---|---|---|---|---|---|
| OME | 1.0 | 11.074 (0.720, 1.602) | 10.905 (0.618, 1.366) | 10.778 (0.390, 1.465) | 10.711 (0.440, 1.105) | 10.983 (0.748, 1.281) | 10.895 (0.565, 1.432) | 11.659 (0.714, 3.676) |
| PAN | 10.931 (0.624, 1.390) | 1.0 | 10.844 (0.511, 1.437) | 10.732 (0.328, 1.543) | 10.661 (0.363, 1.186) | 10.915 (0.621, 1.334) | 10.834 (0.474, 1.480) | 11.548 (0.6176, 3.669) |
| LAN | 11.105 (0.732, 1.619) | 11.185 (0.696, 1.957) | 1.0 | 10.865 (0.381, 1.770) | 10.780 (0.430, 1.386) | 11.079 (0.701, 1.612) | 10.982 (0.598, 1.614) | 11.821 (0.724, 4.295) |
| RAB | 11.285 (0.683, 2.564) | 11.366 (0.648, 3.045) | 11.157 (0.565, 2.622) | 1.0 | 10.915 (0.417, 2.078) | 11.261 (0.636, 2.658) | 11.142 (0.528, 2.660) | 12.130 (0.746, 6.160) |
| ILA | 11.406 (0.905, 2.276) | 11.512 (0.844, 2.753) | 11.282 (0.722, 2.327) | 11.093 (0.481, 2.397) | 1.0 | 11.389 (0.819, 2.355) | 11.261 (0.665, 2.420) | 12.350 (0.911, 5.847) |
| RAN | 11.017 (0.781, 1.338) | 11.093 (0.750, 1.610) | 10.927 (0.620, 1.427) | 10.793 (0.376, 1.573) | 10.720 (0.425, 1.221) | 1.0 | 10.910 (0.601, 1.428) | 11.683 (0.720, 3.876) |
| FAM | 11.117 (0.698, 1.770) | 11.199 (0.676, 2.110) | 11.018 (0.620, 1.672) | 10.876 (0.376, 1.893) | 10.793 (0.413, 1.503) | 11.098 (0.700, 1.664) | 1.0 | 11.849 (0.705, 4.521) |
| PLA | 10.603 (0.272, 1.401) | 10.646 (0.273, 1.620) | 10.549 (0.233, 1.381) | 10.470 (0.162, 1.342) | 10.426 (0.171, 1.098) | 10.594 (0.258, 1.389) | 10.541 (0.221, 1.419) | 1.0 |
Each number is an odds ratio (=row/column), and 95% confidence interval. OME, omeprazole, 20 mg/day; PAN, pantoprazole, 40 mg/day; LAN, lansoprazole, 30 mg/day; RAB, rabeprazole, 20 mg/day; ILA, ilaprazole, 10 mg/day; RAN, ranitidine, 300 mg/day; FAM, famotidine, 40 mg/day; PLA, placebo. Green shading: no significant difference.